PCL Inc
241820
Company Profile
Business description
PCL Inc is engaged in the development of vitro diagnostics products by SG Cap technology used in immobilizing disease biomarkers. It offers blood testing kit, multiplex antigen detection kits, and ultra-low volume non-contact liquid handling.In addition, the company offers platform services, such as sol-gel spotting service that immobilizes the customer's requested material using the SolB reagent; and SG ID service, which provides customers with a molecule of interest immobilized in the SolB reagent and identified.
Contact
Star Valley No. 701
99, Digitalro, 9gi
Geumcheongu
Seoul08510
KORT: +82 7046733433
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
31
Stocks News & Analysis
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.
stocks
Alphabet Earnings: AI Monetisation continues to grow as hardware sales boost results
We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.
stocks
After earnings, we raise our Tesla stock Fair Value Estimate. Are shares a buy?
Solid results included strong full-self driving software uptake and positive free cash flow.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,012.60 | 41.20 | 0.46% |
| CAC 40 | 7,970.00 | 83.04 | 1.05% |
| DAX 40 | 26,039.68 | 335.66 | 1.31% |
| Dow JONES (US) | 52,342.56 | 132.54 | -0.25% |
| FTSE 100 | 10,722.07 | 27.57 | 0.26% |
| HKSE | 22,958.65 | 136.18 | -0.59% |
| NASDAQ | 26,184.72 | 365.13 | -1.38% |
| Nikkei 225 | 64,659.47 | 705.28 | 1.10% |
| NZX 50 Index | 13,736.85 | 26.68 | 0.19% |
| S&P 500 | 7,720.39 | 23.59 | -0.30% |
| S&P/ASX 200 | 8,891.80 | 44.50 | 0.50% |
| SSE Composite Index | 3,651.43 | 30.04 | -0.82% |